No. The applicant should follow CGMP requirements for ANDA submission
as they relate to drug substance and finished drug product. Because the drug
substance quality can affect the drug product stability, the drug substance used
for the ANDA batches (supporting the application) should be of the same
quality intended for the market product. We would consider data from the use
of a different grade drug substance for a product as supporting data.
